Adapta Pacing System Clinical Study
Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Mar 24, 2006
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who have a Class I or II indication for implantation of a dual chamber pacemaker according to ACC/AHA/NASPE guidelines
- • Subjects who have signed a Medical Ethics Committee (MEC) approved Informed Consent Form
- Exclusion Criteria:
- • Subjects with a mechanical tricuspid valve
- • Subjects with a life expectancy less than two years
- • Subjects with a Class III indication for permanent pacing
- • Subjects with lead integrity problems, unless leads are being replaced
About Medtronic Cardiac Rhythm And Heart Failure
Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, , Sweden
Hamburg, , Germany
Graz, , Austria
Bad Nauheim, , Germany
Heerlen, , Netherlands
Prague, , Czech Republic
Belgrade, , Former Serbia And Montenegro
Patients applied
Trial Officials
Adapta Study Team
Study Chair
Medtronic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials